Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Get Free Report)’s stock price hit a new 52-week high during mid-day trading on Wednesday. The company traded as high as $84.00 and last traded at $84.00, with a volume of 10 shares trading hands. The stock had previously closed at $77.40.
Basilea Pharmaceutica Trading Up 8.5%
The company has a debt-to-equity ratio of 0.44, a current ratio of 6.60 and a quick ratio of 5.97. The stock’s 50 day moving average is $76.76 and its 200-day moving average is $69.81.
Basilea Pharmaceutica Company Profile
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Recommended Stories
- Five stocks we like better than Basilea Pharmaceutica
- AST SpaceMobile Has a New Rocket Plan, But Its Cash-Burn Problem Isn’t Going Away
- Powering Up the Moon: Redwire’s $40 Million NASA Award
- Can Constellation Energy’s Contracts Power a Stock Rebound?
- Why Apple Stock Looks Like a Safe Haven After the Midterms
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
